肠道菌群与肿瘤的免疫治疗

Gut microbiome and tumor immunotherapy

肠道菌群是居住于人体肠道内的正常微生物群体。肠道菌群通常与宿主成共生关系,并与宿主的消化、代谢、免疫调节等生理活动息息相关。靶向作用于免疫检查点的免疫检查点抑制剂,作为肿瘤免疫治疗中的新星,有着逆转肿瘤免疫微环境的作用,为肿瘤治疗提供了新的希望。然而研究发现,有部分人群对免疫检查点抑制剂的治疗无响应,而导致其无响应的最主要的原因是肠道菌群的异常。因此,本文对肠道菌群与肿瘤免疫治疗特别是与免疫检查点抑制剂的研究现状进行综述。

Gut microbiome is the normal microflora living in the human body.In normal conditions,it can maintain the symbiotic relationship with the host,taking part in the physiological activities such as digestion,metabolism and immune regulation.As a new way of tumor immunotherapy,immune checkpoint inhibitors can target immune checkpoint and reverse the role of tumor immune microenvironment,thus provide hope for tumor treatment.However,some researches showed that there are some people who do not response to the immune checkpoint inhibitors because of their abnormal gut microbiome.Therefore,in this paper,the current status of research on gut microbiome and immunotherapy,especially on gut microbiome and immune checkpoint inhibitors,are reviewed.